Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • Careers
  • Investors
  • News
    • Press Release Archive
    • Press Statements
    • Podcasts
      • The Antigen Podcast
      • Get Science Podcast
      • Diverse Perspectives Podcast
      • menopause: unmuted
      • Hemcast
    • Contact Media Relations
    • Press Kits & Downloads
      • Company Press Kit
      • Pfizer Oncology Press Kit
      • PSA Narrative
      • RA NarRAtive
      • Rare Disease Gene Therapy Press Kit
      • ATTR-Amyloidosis Press Kit
      • UC Narrative
      • Eczema Inside Out Press Kit
  • Partners
    • Discovery to Pre-candidate
      • Focus Areas
        • Therapeutic Areas
          • Internal Medicine
          • Inflammation and Immunology
          • Oncology
          • Rare Disease
          • Vaccines
        • Therapeutic Modalities and Technology Platforms
          • Drug Safety
          • Gene Therapy
          • Target Sciences
          • Precision Medicine
          • Medicinal Sciences
            • Biologics Product & Process Development
            • Biotherapeutics Discovery
            • Medicine Design
            • Small Molecule Product & Process Development
        • Emerging Science
          • DNA Damage Response
          • Microsatellite Repeat Expansions
          • Senescence
      • Partnering Models
    • Candidate Through Commercialization
      • Focus Areas
        • Internal Medicine
        • Inflammation and Immunology
        • Oncology
        • Rare Disease
        • Vaccines
        • Hospital
    • Pfizer CentreOne
    • Pfizer Ventures
      • Our portfolio

Healthcare Professionals

  • Healthcare Professionals

Connect with Us

  • Connect with Us
    • Email
    • FAQ
    • Privacy Policy (NEW)
    • YouTube
    • Twitter
    • Facebook
    • LinkedIn
    • Instagram
  • Your Health

    • Healthy Living
      • Brain & Nervous System
      • Cardiovascular Health
      • Cold & Flu
      • Digestive Health
      • Healthier Aging
      • Living Tobacco Free
      • Men’s Health
      • Mental Health
      • Nutrition & Fitness
      • Pediatric Health
      • Respiratory Health
      • Skin Health
      • Vaccines & Prevention
      • Women’s Health

    • Disease & Condition
      • Cancer
      • Cardiovascular Diseases & Conditions
      • Diabetes & Metabolic Disorders
      • Immune System Diseases & Conditions
      • Infections & Infectious Diseases
      • Neurological Diseases & Conditions
      • Menopause
      • Rare Disease
      • Vaccine-Related Conditions
      • Skin Diseases & Conditions
      • Atopic Dermatitis
      • Cardiovascular Disease
      • Severe Hypertriglyceridemia

    • Coronavirus disease (COVID-19) Resources

    • Managing your health
      • Caregiving
      • Evaluating Health Information
      • Tracking Your Health
      • Your Medicines
      • Health Literacy

    • Wellness
    Hot Topics

    Maintaining Emotional Well-Being During COVID-19

    Emotional Well-Being Tips for People Living with Chronic Inflammatory Conditions During COVID-19
  • Our Science

    • Driven to Discover the cure

    • Focus Areas
      • Internal Medicine
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Anti Infectives

    • Product Pipeline

    • Clinical Trials
      • Guide to Clinical Trials
      • Find a Trial
      • Expanded Access & Compassionate Use
      • Clinical Trials in Children
      • Partnering with Pfizer
      • Trial Data & Results
      • Research Integrity & Transparency
      • Diversity in Clinical Trials

    • R&D Platforms
      • Biosimilars
      • Gene Therapy
      • Medicinal Sciences
      • Precision Medicine
      • Maternal Immunization

    • Collaboration
      • Partner with Pfizer

    • Research sites

    • Coronavirus disease (COVID-19) Resources
      • All COVID-19 Updates
      • Vaccine Efforts
      • Antiviral Efforts
      • Partnerships & Anti-Infective Efforts
      • Supporting the Fight Against COVID-19
    HOT TOPICS

    MRNA VS. CONVENTIONAL VACCINES

    What Makes an RNA Vaccine Different From a Conventional Vaccine?
  • Our People

    • Meet The Experts
      • Scientists
      • Internal Medicine – Metabolic Disease
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Medical Professionals

    • The Journey

    • Leadership
      • Executives
      • Board Members
      • Company Fact Sheet

    • Diverse Perspectives
      • Diversity & Inclusion
      • Supplier Diversity
    HOT TOPICS

    Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron

    dr_richardson_300x170.jpg

    Working Together to Empower Women

    VizagWomen_300x170.jpg

    • Hot Topics
  • Our Purpose

    • Commitment to Global Health
      • Expanding Access
      • Strengthening Health Systems
      • Providing Disaster & Humanitarian Relief
      • Unleashing the Power of Our Colleagues
      • Highlighting Individual Voices

    • Protecting People and the Environment
      • Pfizer's Green Journey
      • Product Stewardship
      • EHS Governance
      • EHS Supply Chain
      • Key Performance Indicators
      • Health & Safety
      • Human Rights

    • Positions on Health Policies
      • Ready for Cures
      • How does Pfizer price medicines?
      • Value of Medicines
      • Policy Positions
      • Creating Cures Through Facility Investments

    • Transparency
      • Working with Health Care Professionals
      • Transparency in Grants
      • Code of Conduct
      • Corporate Compliance
      • Sales and Marketing Compliance

    • Independent Grants
      • Competitive Grants Program
      • Independent Medical Education
      • Investigator Sponsored Research
      • Quality Improvement
      • COVID-19 Vaccine Grants

    • Contributions & Partnerships
      • Healthcare Charitable Contributions
      • Lobbying & Political Contributions
    HOT TOPICS

    Pfizer Women’s Resource Group

    Media Name: IWD_Pull_up_Banner_300x170.jpg

    • Hot Topics
  • Our Products

    • Product listing

    • How drugs are made
      • Branded vs. Generic
      • Biologics & Biosimilars
      • Commitment to Quality

    • Distributors
      • Pfizer Distributors
      • Greenstone Distributors

    • Medicine Safety
      • Reporting Adverse Events
      • Making Good Treatment Choices
      • Partnering With Patients
      • Health Literacy
      • Medicine Safety Tips for Patients
      • Counterfeiting
      • Unused Medicines

    • Safety Data Sheets

    • Medical Information Contacts

    • Pfizer Global Supply
    HOT TOPICS

    Universal vs. Single Payer Healthcare

    Media Name: universal_healthcare300x170.jpg
  • Careers

    • Working Here
      • Mission & Purpose
      • Culture
      • Diversity & Inclusion
      • Career Growth & Colleague Development
      • Compensation & Benefits
      • Ensuring Corporate Responsibility
    • Search Jobs
    • Student & Early Career
      • Postdoctoral Program
      • US Summer Student Worker Program
      • Opportunities for Veterans
    • Pfizer365.com
    • Our Hiring & Recruiting Process
      • Frequently Asked Questions
      • Tips for Interviewing at Pfizer
    • Connect With Us
  • Investors

    • Investors Overview
      • Why Invest / Our Story
      • Prospective Investors
      • Fact Sheet
    • Events & Presentations
    • Financials
      • Quarterly Reports
      • Annual Reports
      • SEC Filings
      • Interactive Data Filings
    • Investor News
    • Stock Information
      • Historical Price Lookup
      • Investment Calculator
      • Historical Stock Chart & Data
      • Dividend & Split History
      • Stock FAQs
    • Governance
      • Board Committees and Charters
      • The Pfizer Board Policies
      • Corporate Governance FAQs
      • Contact Our Directors
    • Shareholder Services
      • Stock FAQs
      • Advisory Information
      • Cost Basis Calculator
  • News

    • Contact Media Relations
    • Podcasts
    • Press Kits & Downloads
    • Press Release Archive
    • Press Statements
  • Partners
  • Footer links

    • Footer Aside Section1
      • CAREER-SEEKERS
      • INVESTORS
      • News & Media
      • Partners
    • Footer Aside Section 2
      • Healthcare Professionals
      • Business To Business
      • Change Region
      • Sitemap
    • Footer Aside Section3
      • Twitter
      • Facebook
      • Linkedin
      • Instagram
      • Youtube
    • Footer Aside Section4
      • Contact Us
      • Terms of Use
      • Privacy Policy

New Discoveries in Metastatic Breast Cancer Can’t Wait: How Independent Scientific Research is Moving Forward Patient Care

New Discoveries in Metastatic Breast Cancer Can’t Wait: How Independent Scientific Research is Moving Forward Patient Care
OUR SCIENCE/ New Discoveries in Metastatic Breast Cancer Can’t Wait: How Independent Scientific Research is Moving Forward Patient Care
December 4, 2020

Until the 20th century, breast cancer was considered an unspeakable condition, and in general, cancer was seen as an incurable disease.1 Thanks to increases in funding, research, and patient advocacy, there is greater awareness of and care for people living with breast cancer.2 But, for people with the most advanced forms of breast cancer, there still remain significant gaps in funding, research, and care.

The Current State of Metastatic Breast Cancer Research

Every year, millions of people around the world are diagnosed with breast cancer,3 and between 20-30% of these cases will progress to advanced or metastatic breast cancer (mBC).4 While early stage breast cancer can often be cured, mBC remains incurable. An estimated 626,000 women and men die of breast cancer every year, with metastatic disease the cause of nearly all these deaths.5

Clearly, more research is needed to improve outcomes for people living with mBC. Billions of dollars are invested into cancer research every year, but research funding for mBC accounts for only 7% of the total breast cancer research investment.6 At Pfizer, we share the goal of finding cures for mBC with scientists, doctors, patient advocates, and institutions from all over the world. Our shared goal is ultimately why Pfizer administers the Breast Cancer Competitive Research Grants Programs.

Breast Cancer Competitive Research Grant Programs

Through the Breast Cancer Competitive Research Grants programs, Pfizer funds organizations dedicated to mBC research and patient care. Through the most recent rounds of grants, Pfizer received proposals from 68 different countries and awarded funding to 43 new research projects.

These projects support independent clinical research that can improve our understanding of breast cancer epidemiology, patient populations, and the treatment landscape; or expand our understanding of gaps in research, patient care, and patient needs.

If you’re interested in learning more about Pfizer’s Competitive Grants Programs, click here.

Recipients of Pfizer Breast Cancer Competitive Grants

The below projects were selected to receive grants in 2020 through the Pfizer Breast Cancer Competitive Grants Program:

    • Dr. Hikmat Abdel-Razeq, King Hussein Cancer Center, Jordan
      • A study to establish patterns and prevalence of germline BRCA1 & BRCA 2 mutations among high-risk breast cancer patients in the Middle East.
    • Dr. Ivan Bieche, UNICANCER, France
      • A translational study, in partnership with UCBG and GINECO, exploring mechanisms of resistance to first line combination treatment for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2)- advanced breast cancer.
    • Dr. Ivan Bustillo-Chams, Fundacion Hospital Universidad del Norte, Colombia
      • A study to develop a framework of evidence-based tools to guide therapeutic decision making for patients with locally advanced/metastatic HR+/HER2- breast cancer patients in Latin American countries.
    • Dr. Rama Rao Damerla, Kasturba Medical College, Manipal Academy of Higher Education, India
      • A study to improve patient outcomes by increasing access to genetic counseling, testing, and targeted therapies in patients with hereditary breast cancer.
    • Dr. Ho Gwo Fuang, Cancer Research Malaysia, Malaysia
      • A study that assesses PARP inhibition in Asian metastatic breast cancer patients with a homologous recombination deficiency signature.
    • Dr. Seock-Ah Im, Seoul National University, South Korea
      • A study investigating the role of biomarkers other than germline BRCA mutation in monotherapy treatment of advanced breast cancer.
    • Dr. Takayuki Iwamoto, Okayama University Hospital, Japan
      • A study to determine whether the 21-gene recurrence score can predict the progression of advanced/metastatic HR+/HER2- breast cancer.
    • Dr. Soo Chin Lee, National University Cancer Institute of Singapore, Singapore
      • A study that develops an artificial intelligence chatbot to provide customized, pre-consultation education for probands suspected to have hereditary breast ovarian cancer.
    • Dr. Wendy Chan Wing Lok, The University of Hong Kong, China
      • A study to investigate the feasibility and efficacy of a smartphone app-based education program on exercise capacity, symptom management, and health-related quality of life in patients with adjuvant or metastatic breast cancer.
    • Dr. Taisa Manuela Bonfim Machado Lopes, Federal University of Bahia, Brazil
      • An analysis of clinical, molecular, and epidemiological characteristics between male and female breast cancer patients in Brazil.
    • Dr. Solomon Kibudde, Uganda Cancer Institute, Uganda
      • A study that strengthens breast cancer care coordination through training primary care providers and community patient navigators.
    • Dr. Dal Molin and Dr. Thiago William Jorge, BP - A Beneficência Portuguesa de São Paulo, Brazil
      • A study to evaluate patient-reported quality of life outcomes in metastatic breast cancer patients using a smartphone app.
    • Dr. Afonso Nazario and Dr. Vanessa Monteiro Sanvido, Universidade Federal de São Paulo, Brazil
      • A prospective study of outcomes in relation to health care coverage of patients with HR+/HER2+ metastatic breast cancer in Brazil.
    • Dr. Nixon Niyonzima, Uganda Cancer Institute, Uganda
      • A longitudinal analysis of circulating tumor DNA in metastatic breast cancer patients to assess treatment response and identify potential mutations involved in acquired resistance.
    • Dr. Adeleye Omisore, Obafemi Awolowo University Teaching Hospital Complex, Nigeria
      • A study that establishes a novel, community-based breast cancer program to address delayed presentation, and lack of access to diagnostics and treatment facilities in South-West Nigeria.
    • Dr. Alicia Okines, The Royal Marsden Hospital NHS Foundation Trust, England
      • A study that evaluates combination treatments for estrogen receptor positive (ER+)/  HER2- breast cancer patients.
    • Dr. Melinda Telli, Stanford University School of Medicine, United States
      • A study that looks into PARP inhibitor monotherapy for PALB2-mutated advanced breast cancer.
    • Dr. Mylin A. Torres, Winship Cancer Institute, Emory University School of Medicine, United States
      • Multi-institutional pilot study of PARP inhibition, radiotherapy, and immunotherapy in patients with gBRCA wild-type, PD-L1+ metastatic triple negative breast cancer. 
    •  Dr. Hongxia Wang, Shanghai General Hospital, China
      • A retrospective analysis of gene mutations and resistance/sensitivity in the PALOMA 2 trial.
 
 

1. Osuch, Janet R, et al. “A Historical Perspective on Breast Cancer Activism in the United States: from Education and Support to Partnership in Scientific Research.” Journal of Women's Health (2002), Mary Ann Liebert, Inc., Mar. 2012, www.ncbi.nlm.nih.gov/pmc/articles/PMC3298674/.

2. Braun S. The History of Breast Cancer Advocacy. The Breast Journal. 2003;9(42):S101-S103.

3. World Health Organization. Breast Cancer Fact Sheet. https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. Accessed November 13, 2020.

4. O’Shaughnessy. “Extending survival with chemotherapy in metastatic breast cancer.” Oncologist 2005;10 Suppl 3:20-9.

5. World Health Organization. Globalcan 2018: Breast Cancer. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. Accessed December 2020.

6. MBC Alliance. Metastatic Breast Cancer Landscape Analysis (2014).

  •  

At Pfizer, we share the goal of finding cures for mBC with scientists, doctors, patient advocates, and institutions from all over the world.

Related Hot Topics
Some older people living with cancer aim for remission but lack needed resources to help make treatment decisions, global survey reveals
Some older people living with cancer aim for remission but lack needed…
Improving Care and Support for People Living with Breast Cancer
Improving Care and Support for People Living with Breast Cancer
FYMBCV_Meredith_Teri_1000x450.jpg
Meredith Vieira Honors Her Grandmother by Helping People Living with Metastatic…
cancer_and_enzymes_300x170.jpg
Attacking Cancer Cells That Develop Resistance
pfizer_get-science_smc_korean-breast-cancer_300x170.jpg
Using ‘Omics to Understand the Rise in Breast Cancers Among Young Asians
my_sisters_breast_cancer_diagnosis300x170.jpg
My Sister's Breast Cancer Diagnosis and What It Meant for Me
breast_cancer_original300x170.jpg
Get the Facts About Breast Cancer
TarahHarvey300x170.jpg
A Look at Hereditary Breast Cancer and Genetic Testing
Tags
Breast cancer
Metastatic Breast Cancer
Show
Hide

Footer menu

  • Your Health
    • Healthy Living
    • Disease Conditions
    • Manage Your Health
  • Our Science
    • Therapeutic Areas
    • Product Pipeline
    • Clinical Trials
    • R&D Platforms
    • Collaboration
    • Research SItes
  • Our People
    • Meet the Experts
    • The Journey
    • Leadership
    • Diverse Perspectives
  • Our Purpose
    • Commitment To Global Health
    • Positions on Health Policies
    • Transparency
    • Contributions & Partnerships
  • Our Products
    • Product Listing
    • How Drugs are Made
    • Distributors
    • Global Product Information Contacts

Footer aside

  • Footer Aside Section1
    • CAREER-SEEKERS
    • INVESTORS
    • News & Media
    • Partners
  • Footer Aside Section 2
    • Healthcare Professionals
    • Business To Business
    • Change Region
    • Sitemap
  • Footer Aside Section3
    • Twitter
    • Facebook
    • Linkedin
    • Instagram
    • Youtube
  • Footer Aside Section4
    • Contact Us
    • Terms of Use
    • Privacy Policy
Pfizer Logo Footer

Copyright © 2002-2021 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of the United States.
The products discussed herein may have different labeling in different countries.